Department of Food and Nutritional Sciences, University of Reading, Whiteknights Campus, PO Box 226, Reading RG6 6AP, UK.
Cell Metab. 2017 Jul 5;26(1):6-7. doi: 10.1016/j.cmet.2017.06.009.
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.
基于胰高血糖素样肽 1（GLP-1）的疗法可有效降低 2 型糖尿病患者的高血糖水平，但部分患者会出现 GLP-1 抵抗。近期《细胞代谢》杂志上，Grasset 等人（2017）证明肠道细菌通过肠神经系统中的一氧化氮信号调节 GLP-1 敏感性。
